Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
80
K
Drugs & Biologics
45
K
Targets
962
K
Organizations
884
K
Clinical Trials
66
M
Literatures
16
M
Patents
Recent blog posts
Nitroxoline: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
Nitroxoline: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
23 February 2024
APL-1202 (nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities.
Read →
FDA Grants Priority Review for argenx's VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Latest Hotspot
3 min read
FDA Grants Priority Review for argenx's VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
23 February 2024
argenx has reported that the FDA has granted priority review status for their updated biologics application for VYVGART Hytrulo, aimed at treating chronic inflammatory demyelinating polyneuropathy.
Read →
The Synapse User's Toolkit: Tips for Searching Biotin
Drug Insights
2 min read
The Synapse User's Toolkit: Tips for Searching Biotin
23 February 2024
Biotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins.
Read →
Check out our latest report
Global Drug R&D Express (Dec 2023)

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Nov 2023)

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Oct 2023)

Global Drug R&D Express (Oct 2023)

The data in this report has been sourced from Patsnap Synapse, a novel AI-powered database that offers a search and association platform with intuitive interfaces, curated content, and integrated access to massive information sources that connect company data, diseases, targets, and clinical studies to biological and chemical entities. Based on data from the Synapse database, we recently published Global Innovative Drug Report, which offers a comprehensive overview of the latest advancements in the pharmaceutical industry and analysis of each selected drug, examining their snapshot, R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors. The report consists of four parts: >>1.First Approved Drugs in October 2023; >>2. New Drug Analysis; >>3.Global Drugs under Expedited Review Pathway in October 2023; >>4. Analysis of Selected ERP Drugs.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.